Population pharmacokinetic‐pharmacodynamic modeling of serum biomarkers as predictors of tumor dynamics following lenvatinib treatment in patients with radioiodine‐refractory differentiated thyroid cancer (RR‐DTC)
CPT: Pharmacometrics & Systems Pharmacology · 2024
DOI: 10.1002/psp4.13130 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift CPT: Pharmacometrics & Systems Pharmacology, 2024. Verfasst von Oneeb Majid und 10 weiteren Autor:innen. Beteiligte Einrichtung: Eisai Ltd., Hatfield, UK. Hauptthemen laut MEDLINE: Quinolines, Phenylurea Compounds, Thyroid Neoplasms, Iodine Radioisotopes. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Eisai Ltd., Eisai Co., Eisai Inc.
Abstract (Originalsprache)
Lenvatinib is a receptor tyrosine kinase (RTK) inhibitor targeting vascular endothelial growth factor (VEGF) receptors 1–3, fibroblast growth factor (FGF) receptors 1–4, platelet‐derived growth factor receptor‐α (PDGFRα), KIT, and RET that have been implicated in pathogenic angiogenesis, tumor growth, and cancer. The primary objective of this work was to evaluate, by establishing quantitative relationships, whether lenvatinib exposure and longitudinal serum biomarker data (VEGF, Ang‐2, Tie‐2, and FGF‐23) are predictors for change in longitudinal tumor size which was assessed based on data from 558 patients with radioiodine‐refractory differentiated thyroid cancer (RR‐DTC) receiving either lenvatinib or placebo treatment. Lenvatinib PK was best described by a 3‐compartment model with simultaneous first‐ and zero‐order absorption and linear elimination from the central compartment with significant covariates (body weight, albumin ULN, RR‐DTC, RCC, HCC subjects, and concomitant CYP3A inhibitors). Except for body weight, none of the covariates have any clinically meaningful effect on exposure to lenvatinib. Longitudinal biomarker measurements over time were reasonably well defined by a PK/PD model with common EC 50 , E max , and a slope for disease progression for all biomarkers. Longitudinal tumor measurements over time were reasonably well defined by a tumor growth inhibition E max model, which in addition to lenvatinib exposure, included model‐predicted relative changes from baseline over time for Tie‐2 and Ang‐2 as having significant association with tumor response. The developed PK/PD models pave the way for dose optimization and potential prediction of clinical response.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Eisai Ltd., Hatfield, UK.
- Eisai Co., Ltd., Tokyo, Japan.
- Eisai Inc., Nutley, New Jersey, USA.
ORCID-Profile: Oneeb Majid, Seiichi Hayato
Förderung
- Eisai Ltd.
- Eisai Co.
- Eisai Inc
Zitieren
APA
Majid, O., Hayato, S., Sreerama Reddy, S. H., Lalovic, B., Hihara, T., Hoshi, T., Funahashi, Y., Aluri, J., Takenaka, O., Yasuda, S., & Hussein, Z. (2024). Population pharmacokinetic‐pharmacodynamic modeling of serum biomarkers as predictors of tumor dynamics following lenvatinib treatment in patients with radioiodine‐refractory differentiated thyroid cancer (RR‐DTC). CPT: Pharmacometrics & Systems Pharmacology. https://doi.org/10.1002/psp4.13130
Vancouver
Majid O, Hayato S, Sreerama Reddy SH, Lalovic B, Hihara T, Hoshi T, et al. Population pharmacokinetic‐pharmacodynamic modeling of serum biomarkers as predictors of tumor dynamics following lenvatinib treatment in patients with radioiodine‐refractory differentiated thyroid cancer (RR‐DTC). CPT: Pharmacometrics & Systems Pharmacology. 2024. doi:10.1002/psp4.13130
BibTeX
@article{Majid2024,
author = {Majid, Oneeb and Hayato, Seiichi and Sreerama Reddy, Sree Harsha and Lalovic, Bojan and Hihara, Taro and Hoshi, Taisuke and Funahashi, Yasuhiro and Aluri, Jagadeesh and Takenaka, Osamu and Yasuda, Sanae and Hussein, Ziad},
title = {Population pharmacokinetic‐pharmacodynamic modeling of serum biomarkers as predictors of tumor dynamics following lenvatinib treatment in patients with radioiodine‐refractory differentiated thyroid cancer (RR‐DTC)},
journal = {CPT: Pharmacometrics & Systems Pharmacology},
year = {2024},
doi = {10.1002/psp4.13130}
}
EUVIMED